ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÎâС½£ÍŶӷ¢Ã÷սʤ³¦°©»¯ÁÆÄÍÒ©ÐÂÕ½ÂÔ

¸å¼þȪԴ£º£º£ºÁ¥ÊôµÚÁùÒ½Ôº ±à¼­£º£º£ºÖ£Áú·É¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¼òÎÄÑî¡¢´÷Ï£°²¡¢ÓàÕÕÁÁ£©ÔõÑùսʤ»¯ÁÆÄÍÒ©ÊÇÒ»Ö±ÊÇÖ×ÁöÑо¿ÁìÓòµÄÈÈÃźÍÄѵãÎÊÌâ¡£¡ £¡£»£»ùÓÚ¶à×éѧ²âÐòÊý¾ÝѰÕÒÖÎÁưе㣬£¬£¬²¢ÔÚ»¼ÕßÖ×ÁöȪԴµÄÄ£×ÓÖоÙÐÐÒ©ÎïÊÔÑéÑéÖ¤£¬£¬£¬ÊÇÏÖÔÚ¿ª·¢°ÐÏòÒ©ÎïµÄÓÐÓÃÊÖ¶ÎÖ®Ò»¡£¡ £¡£¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÎâС½£¿ÎÌâ×éÓëngµç×ÓÓÎÏ·Ö×Áö·ÀÖÎÖÐÐÄÌ·¾²¿ÎÌâ×éÔÚAdvanced ScienceÔÓÖ¾£¨IF£º£º£º16.8£©ÉϽÒÏþÁËÌâΪ¡°Inhibition of the PLK1-coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer¡±µÄÑо¿ÂÛÎÄ¡£¡ £¡£¸ÃÑо¿Ê¹ÓÃ×éѧ²âÐòÊý¾ÝÕûºÏÍÚ¾ò³ö½áÖ±³¦°©»¯ÁÆÄÍÒ©µÄDZÔÚÏà¹Ø°ÐµãPLK1,²¢ÔÚ¶à¸ö»¼ÕßÖ×ÁöȪԴµÄÄ£×ÓÉϾÙÐÐÁËÒ©ÎïÊÔÑéÑéÖ¤£¬£¬£¬ÏµÍ³µØÌ½Ë÷ÁËPLK1ÒÖÖÆ¼ÁÔÚ½áÖ±³¦°©ÖеÄÖÎÁÆ»úÖÆ¡£¡ £¡£¸ÃÑо¿Ð§¹û·¢Ã÷ÁªºÏʹÓÃPLK1ÒÖÖÆ¼ÁÄÜÏÔÖøÌá¸ß°ÂɳÀû²¬¿¹Ö×Áö×÷Ó㬣¬£¬ÕâΪ»¯ÁÆÄÍÒ©»òÕßÖ×Áö¸´·¢µÄ³¦°©»¼ÕßÌṩÁËеÄÖÎÁÆË¼Ð÷¡£¡ £¡£

³¦°©µÄ»¯ÁÆÄÍÒ©ÊÇÁÙ´²ÖÎÁÆÖÐÎÞ·¨»Ø±ÜµÄÎÊÌ⣬£¬£¬Ï൱һ²¿·Ö»¼ÕßÔÚ¾­Óɳ¦°©µÄ¸ùÖÎÐÔÖÎÁƺ󣬣¬£¬È´Òò»¯ÁÆÄÍÒ©¶ø±¬·¢Ö×Áö¸´·¢ºÍ×ªÒÆ£¬£¬£¬×îºóÒòÎÞÒ©¿ÉÓöøµ¼ÖÂÖ×ÁöÎÞÏÞÖÆµØ²¥É¢Éú³¤¡£¡ £¡£ÎªÁËÍÚ¾òսʤ»¯ÁÆÄÍÒ©µÄDZÔÚÖÎÁưе㣬£¬£¬Ñо¿ÍŶÓÊ×ÏȶÔ54Àý½áÖ±³¦°©Ö×Áö×éÖ¯ºÍÅä¶ÔµÄ°©ÅÔð¤Ä¤×éÖ¯µÄ»ùÒòоƬÊý¾Ý¾ÙÐÐÕûºÏÆÊÎö£¬£¬£¬·¢Ã÷PLK1ÐźÅͨ·̫¹ý»î»¯£¬£¬£¬ÌáÐÑPLK1¿ÉÄÜÊǽáÖ±³¦°©µÄÓÐÓÃÖÎÁưбê¡£¡ £¡£±ðµÄ£¬£¬£¬Ñо¿ÍŶÓÔÚ343Àý½áÖ±³¦°©²¡ÈËÐÐÁÐÖжÔPLK1ºÍp-PLK1µÄ±í´ïÇéÐμ°¶ÔÓ¦µÄÔ¤ºó¾ÙÐÐÆÊÎö£¬£¬£¬·¢Ã÷¸ß±í´ïPLK1ºÍp-PLK1µÄ»¼ÕßÖ×Áö¸´·¢Âʽϸߣ¬£¬£¬ÉúÑÄÆÚ¸ü¶Ì¡£¡ £¡£Ñо¿ÍŶӽøÒ»²½ÍøÂçÁË27Àý½áÖ±³¦°©»¼ÕßÔÚ»¯ÁÆÇ°ºÍÖ×Áö¸´·¢ºóµÄÅä¶ÔÑù±¾£¬£¬£¬·¢Ã÷Ö×Áö¸´·¢ºóPLK1ºÍp-PLK1±í´ïÏÔÖøÔö¸ß£¬£¬£¬ÌáÐÑ¿ÉÄÜÓëÖ×ÁöµÄ»¯ÁÆÄÍÒ©Ïà¹Ø¡£¡ £¡£Í¬Ê±PLK1ÒÖÖÆ¼Á¿ÉÏÔÖøÔöÇ¿°ÂɳÀû²¬¶ÔÖ×Áöϸ°ûµÄÒÖÖÆÐ§¹û£¬£¬£¬ÕâÒ»±íÐÍÔÚ½áÖ±³¦°©Ï¸°ûϵ¡¢»¼ÕßÖ×ÁöȪԴµÄÀàÆ÷¹ÙÄ£×Ó¼°PDXÄ£×ÓÉÏ»ñµÃÑéÖ¤¡£¡ £¡£ÎªÌ½Ë÷ÆäÒ©Àí»úÖÆ£¬£¬£¬Ñо¿Õßͨ¹ýÕûºÏÆÊÎöRNA-seqºÍChIP-seqÊý¾Ý£¬£¬£¬·¢Ã÷CDC7¿ÉÄÜÊÇPLK1ÒÖÖÆ¼ÁÔöÃô°ÂɳÀû²¬Ò©Ð§µÄÖ÷ÒªÏÂÓηÖ×Ó£¬£¬£¬c-MYC¿Éͨ¹ýת¼µ÷¿ØCDC7¶øÊ©Õ¹Òªº¦µ÷¿Ø×÷Ó㬣¬£¬ÌáÐÑPLK1-MYC-CDC7ÐźÅͨ·¿ÉÄÜÔÚµ÷¿Ø½áÖ±³¦°©»¯ÁÆÄÍÒ©ÖÐʩչÖ÷Òª¹¦Ð§¡£¡ £¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1 °ÐÏòÒÖÖÆPLK1-MYC-CDC7ÐźÅͨ·¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬Ãô¸ÐÐÔµÄÖÎÁÆÕ½ÂÔ

Ñо¿ÍŶÓͨ¹ýÕûºÏÆÊÎö´ó¹æÄ£½áÖ±³¦°©»¼ÕßÑù±¾Êý¾Ý£¬£¬£¬·¢Ã÷PLK1¿ÉÄÜÊǽáÖ±³¦°©µÄDZÔÚÒ©Îï°Ðµã¡£¡ £¡£²¢·¢Ã÷»¯Áƺ󸴷¢µÄ»¼ÕßÖ×Áö×éÖ¯ÖÐPLK1¸ß±í´ï£¬£¬£¬ÌáÐÑ¿ÉÄÜÓ뻯ÁÆÄÍÒ©Ïà¹Ø£¨Í¼2£©¡£¡ £¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2 »¯Áƺ󸴷¢µÄ»¼ÕßÖ×Áö×éÖ¯ÖÐPLK1¸ß±í´ï

ΪÁËÑéÖ¤Ò©ÎïÁÆÐ§£¬£¬£¬Ñо¿ÍŶÓÔÚ½áÖ±³¦°©Ï¸°ûϵ¡¢»¼ÕßÖ×ÁöȪԴµÄÀàÆ÷¹ÙÄ£×Ó¼°PDXÄ£×ÓÉϾÙÐÐҩЧʵÑ飬£¬£¬Ö¤Êµ¸Ã°ÐÏòÒ©Îï¿ÉÌá¸ß°ÂɳÀû²¬ÁÆÐ§£¬£¬£¬ÎªÁÙ´²×ª»¯ÖÎÁÆÌṩÁ˸»×ãµÄÁÙ´²Ç°Ñо¿Êý¾Ý£¨Í¼3£©¡£¡ £¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ3 °ÐÏòÖÎÁÆÔÚÀàÆ÷¹Ù¼°PDXÄ£×ÓÉϾßÓÐÏÔÖøÒ©Ð§

ͨ¹ýÕûºÏÆÊÎöRNA-seqºÍChIP-seqÊý¾Ý£¬£¬£¬·¢Ã÷PLK1-MYC-CDC7ÐźÅͨ·ÔÚµ÷¿Ø½áÖ±³¦°©»¯ÁÆÄÍÒ©ÖÐʩչÖ÷Òª¹¦Ð§£¬£¬£¬ÎªPLK1ÒÖÖÆ¼ÁµÄÁÙ´²ÔËÓÃÌṩÁËÃ÷È·µÄÒ©Àí»úÖÆ£¨Í¼4£©¡£¡ £¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ4 PLK1ÒÖÖÆ¼ÁÓë°ÂɳÀû²¬ÁªºÏʹÓõÄÒ©Àí»úÖÆ

Ñо¿ÍŶÓ̽ÌÖÁËPLK1ÒÖÖÆ¼ÁÔÚ½áÖ±³¦°©ÖеÄÖÎÁÆÇ±ÄÜ£¬£¬£¬ÆÊÎöÁËPLK1ÒÖÖÆ¼ÁÓë°ÂɳÀû²¬ÁªºÏʹÓõÄÒ©Àí»úÖÆ£¬£¬£¬¼´PLK1ÒÖÖÆ¼Á¿ÉÒÔͨ¹ýÒÖÖÆc-MYC¶ÔCDC7µÄת¼»îÐÔ£¬£¬£¬½ø¶øµ¼ÖÂCDC7µÄÂѰ×ˮƽϵ÷£¬£¬£¬²¢×îÖÕÌá³öÁ˰ÐÏòÒÖÖÆPLK1-MYC-CDC7ÐźÅͨ·¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬Ãô¸ÐÐÔµÄÖÎÁÆÕ½ÂÔ¡£¡ £¡£

ngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÎâС½£Ö÷ÈÎҽʦ¡¢ngµç×ÓÓÎÏ·Ö×Áö·ÀÖÎÖÐÐÄÌ·¾²Ñо¿Ô±ºÍngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½ÔºÀ¼Æ½½ÌÊÚΪ±¾ÂÛÎĵÄͨѶ×÷Õߣ¬£¬£¬ÓàÕÕÁÁ²©Ê¿ºó¡¢µËÅô²©Ê¿ÒÔ¼°³ÂîÚ·æÖ÷ÖÎҽʦΪ±¾ÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬£¬±¾Ñо¿»¹»ñµÃÁËÐÂ¼ÓÆÂ»ùÒò×éÑо¿ÔºÓÚÇ¿½ÌÊڵĴóÁ¦Ö§³Ö¡£¡ £¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://doi.org/10.1002/advs.202100759

¡¾ÍøÕ¾µØÍ¼¡¿